Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Novel 1,4-Dihydropyrido[2,3-B]Pyrazine-2,3-Dione Derivatives for Treating Cancer and Other Disorders Associated with KRAS Activity.

Anti-cancer agents in medicinal chemistry - 1 Jan 2023

De Surya K

Abstract excerpt

This application describes the synthesis of new 1,4-dihydropyrido[2,3-b]pyrazine-2,3-dione derivatives and methods of using these compounds as KRAS covalent inhibitors. This class of compounds is useful for treating cancer and other diseases associated with KRAS activity.

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Colorectal Neoplasms
Share to Mutation
Share to Proto-Oncogene Proteins p21(ras)

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 36443974
DOI: 10.2174/1871520623666221128110638

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Novel 1,4-Dihydropyrido[2,3-B]Pyrazine-2,3-Dione Derivatives for Treating Cancer and Other Disorders Associated with KRAS Activity.PMID 36443974Read ↗

Insights into direct KRAS inhibition strategies for cancer treatment.Semantic proximity Read ↗

Targeting mutant KRAS.Semantic proximity Read ↗

Multiple medicinal chemistry strategies of targeting KRAS: State-of-the art and future directions.Semantic proximity Read ↗

Novel approaches for the development of direct KRAS inhibitors: structural insights and drug design.Semantic proximity Read ↗

A bright future for KRAS inhibitors.Semantic proximity Read ↗

Small-Molecule Inhibitors Directly Targeting KRAS as Anticancer Therapeutics.Semantic proximity Read ↗

The Research Progress of Direct KRAS G12C Mutation Inhibitors.Semantic proximity Read ↗

Current Strategies and Future Dimensions in the Development of KRAS Inhibitors for Targeted Anticancer Therapy.Semantic proximity Read ↗

Annual review of KRAS inhibitors in 2022.Semantic proximity Read ↗

From KRASG12D to Pan-KRAS Inhibitors─A Journey Enabled by Synthetic Innovation and Structure-Based Drug Design.Semantic proximity Read ↗

Recent advances in the development of inhibitors targeting KRAS-G12C and its related pathways.Semantic proximity Read ↗

JDQ443, a Structurally Novel, Pyrazole-Based, Covalent Inhibitor of KRASG12C for the Treatment of Solid Tumors.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.